bupropion and Body Weight

bupropion has been researched along with Body Weight in 36 studies

Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.

Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.

Research

Studies (36)

Authors

Clinical Trials (6)

Trial Overview

Trial Outcomes

Binge Eating Frequency (Continuous)

Binge eating will be assessed by interview and self-report and the primary outcome is frequency. Frequency also is defined continuously (analyzed dimensionally). (NCT02317744)
Timeframe: 6 month follow-up (an average of 6 months following treatment)

Binge Eating Frequency (Continuous)

Binge eating will be assessed by interview and self-report and the primary outcome is frequency. Frequency also is defined continuously (analyzed dimensionally). (NCT02317744)
Timeframe: Post-treatment (at 3 months)

Body Mass Index (BMI)

BMI is calculated using measured height and weight. (NCT02317744)
Timeframe: 6 month follow-up (an average of 6 months following treatment)

Body Mass Index (BMI)

BMI is calculated using measured height and weight. (NCT02317744)
Timeframe: Post-treatment (at 3 months)

Body Weight- Proportion of Subjects With ≥10% Decrease

(NCT00474630)
Timeframe: Baseline, 56 weeks

Change in Diastolic Blood Pressure

(NCT00474630)
Timeframe: Baseline, 56 weeks

Change in Fasting Blood Glucose Levels

(NCT00474630)
Timeframe: Baseline, 56 weeks

Change in Fasting HDL Cholesterol Levels

(NCT00474630)
Timeframe: Baseline, 56 weeks

Change in Fasting Insulin Levels, Using Log-transformed Data

(NCT00474630)
Timeframe: Baseline, 56 weeks

Change in Fasting LDL Cholesterol Levels

(NCT00474630)
Timeframe: Baseline, 56 weeks

Change in Fasting Triglycerides Levels, Using Log-transformed Data

(NCT00474630)
Timeframe: Baseline, 56 weeks

Change in Food Craving Inventory Carbohydrates Subscale Score

The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00474630)
Timeframe: Baseline, 56 weeks

Change in Food Craving Inventory Sweets Subscale Score

The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00474630)
Timeframe: Baseline, 56 weeks

Change in HbA1c Levels

(NCT00474630)
Timeframe: Baseline, 56 weeks

Change in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data

(NCT00474630)
Timeframe: Baseline, 56 weeks

Change in HOMA-IR Levels, Using Log-transformed Data

HOMA-IR= Homeostasis Model Assessment-Insulin Resistance (NCT00474630)
Timeframe: Baseline, 56 weeks

Change in IDS-SR Total Scores

IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression. (NCT00474630)
Timeframe: Baseline, 56 weeks

Change in IWQOL-Lite Total Scores

IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment (NCT00474630)
Timeframe: Baseline, 56 weeks

Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire

Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult (NCT00474630)
Timeframe: Baseline, 56 weeks

Change in Systolic Blood Pressure

(NCT00474630)
Timeframe: Baseline, 56 weeks

Change in Waist Circumference

(NCT00474630)
Timeframe: Baseline, 56 weeks

Co-primary: Body Weight- Mean Percent Change

(NCT00474630)
Timeframe: Baseline, 56 weeks

Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease

(NCT00474630)
Timeframe: Baseline, 56 weeks

HbA1c- Proportion of Subjects With HbA1c <6.5% at Endpoint

(NCT00474630)
Timeframe: Baseline, 56 weeks

HbA1c- Proportion of Subjects With HbA1c <7% at Endpoint

(NCT00474630)
Timeframe: Baseline, 56 weeks

Percent of Subjects Discontinuing Due to Poor Glycemic Control

Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed. Odds ratio not calculated as there were no subjects in the NB32 group that discontinued due to poor glycemic control. (NCT00474630)
Timeframe: Baseline, 56 weeks

Percent of Subjects Requiring Rescue Medications for Diabetes

(NCT00474630)
Timeframe: Baseline, 56 weeks

Percent of Subjects With Dose Increase in Oral Antidiabetes Medications

(NCT00474630)
Timeframe: Baseline, 56 weeks

Percent of Subjects With Dose Reduction in Oral Antidiabetes Medications

(NCT00474630)
Timeframe: Baseline, 56 weeks

Absolute Change in Body Weight From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Change Fasting Insulin From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Change in Diastolic Blood Pressure From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Change in Fasting High-density Lipoprotein Cholesterol From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Change in Fasting Low-density Lipoprotein Cholesterol From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Change in Fasting Plasma Glucose From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Change in Fasting Triglycerides From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Change in Heart Rate From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Change in Homeostasis Model Assessment-insulin Resistance (HOMA-IR) From Baseline to Week 26

HOMA-IR is an insulin sensitivity index that is calculated as HOMA-IR = (Glucose * Insulin) / 405, where glucose is in mass units (mg/dL) and insulin is in µIU/mL. Higher values indicate lower insulin sensitivity. (NCT01764386)
Timeframe: Baseline to Week 26

Change in Patient-reported Arizona Sexual Experiences Scale (ASEX) Total Scores From Baseline to Week 26

Arizona Sexual Experiences (ASEX) scale is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Possible total scores range from 5 to 30, with the higher scores indicating more sexual dysfunction. (NCT01764386)
Timeframe: Baseline to Week 26

Change in Patient-reported Binge Eating Scale (BES) Total Scores From Baseline to Week 26

The BES is a 16-item questionnaire that identifies different levels of binge-eating severity, with total scores ranging between 0-46. BES scores were categorized as follows: None = Scores ≤17 indicated no significant binge eating, Moderate = scores from 18 to 26 (inclusive), Severe = scores ≥27 indicated severe levels of binge eating. (NCT01764386)
Timeframe: Baseline to Week 26

Change in Patient-reported Impact of Weight on Quality of Life-Lite Questionnaire (IWQOL-Lite) Total Score From Baseline to Week 26

Impact of Weight on Quality of Life-Lite Questionnaire (IWQOL-Lite) is a self-reported assessment of perceived effect of weight on quality of life. It consists of 31 items organized in 5 domains (physical function, self-esteem, sexual life, public distress and work). IWQOL-Lite total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment. (NCT01764386)
Timeframe: Baseline to Week 26

Change in Systolic Blood Pressure From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Change in Waist Circumference From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Percent Change in Body Weight From Baseline (Day 1) to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Percentage of Subjects Achieving a Loss of at Least 10% of Baseline Body Weight at Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Percentage of Subjects Achieving a Loss of at Least 15% of Baseline Body Weight at Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Percentage of Subjects Achieving a Loss of at Least 5% of Baseline Body Weight at Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Depressive Symptoms at Baseline and Measured Monthly, as Measured by the Structured Interview Guide for the Hamilton Depression Rating - Seasonal Affective Disorder (SIGH-SAD)

Clinician-rated measure of mood; evaluates classical 21 Hamilton Depression items, and 8-item subscale measuring atypical depression symptoms which commonly occur during SAD episodes. Score ranges from 0-89, higher scores indicate higher levels of depression. (NCT00502320)
Timeframe: Monthly for duration of treatment (up to 4 months)

Depressive Symptoms at Baseline and Measured Monthly, as Measured by the Zung Depression Scale (ZDS)

Self-rated scale to measure severity of depressive symptoms. Score ranges from 25-100, higher scores reflect more depression. (NCT00502320)
Timeframe: Monthly for duration of treatment (up to 4 months)

Sleep Satisfaction at Baseline and Measured Monthly, as Measured by the Pittsburgh Sleep Quality Index (PSQI)

Self-rated scale to measure quality of sleep via questions regarding sleep latency, duration, efficiency, disturbances, use of sleep medication, and daytime dysfunction. Score ranges from 0-21, higher scores represent more significant sleep disturbance. (NCT00502320)
Timeframe: Monthly for duration of treatment (up to 4 months)

Reviews

6 reviews available for bupropion and Body Weight

Trials

15 trials available for bupropion and Body Weight

Other Studies

15 other studies available for bupropion and Body Weight